Philogen SpA ( (IT:PHIL) ) has shared an announcement.
Philogen purchased 1,439 treasury shares on Euronext Milan between November 9 and 13, 2026, at an average €20.9738 per share, spending €30,181.28; the purchases represented 0.0035% of share capital. Since the program began, the company has bought 37,588 shares worth €828,677.88, or 0.0926% of share capital, and held 400,387 ordinary shares, or 0.9859%, as of November 13.
The most recent analyst rating on (IT:PHIL) stock is a Hold
with a EUR21.00 price target.
To see the full list of analyst forecasts on Philogen SpA stock,
see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products for diseases with high mortality rates. It primarily develops targeted anticancer drugs using high-affinity ligands for tumor markers, with a vascular-targeting approach that delivers potent agents to tumors while sparing healthy tissue.
YTD Price Performance: -6.76%
Average Trading Volume: 16,978
Technical Sentiment Signal: Sell
Current Market Cap: €615.6M
Find detailed analytics on PHIL stock on TipRanks’ Stock Analysis page.
Trending Articles:
This article was AI-generated from the company’s official filing, with automated quality checks and editorial spot-checks.


